Life With Phenylketonuria. Adult Neurological Outcome of PCU Screened Patients From 1971 to 2002.

University Hospital, Lille138 enrolled

Overview

You were detected during the neonatal period for phenylketonuria and you benefited from the diagnosis of an adapted dietetic care, and this for a variable duration according to the recommendations followed at that time. The recommendations for the management of phenylketonuria have evolved considerably over time, lengthening the duration, rigor of the diet and target rates. However, few studies have been able to determinate the influence of metabolic balance and pediatric management on fate in adulthood. As you know, the current recommendations are more stringent and prolonged, without taking into account the pediatric data of today's adult patients. The objective of this study, which is aimed at all adult patients screened and followed by Lille University Hospital, according to the same care methods, allowing a homogeneous monitoring of patients, is to assess the influence of pediatric care (duration of the diet, metabolic balance, compliance) on the future in adulthood. This retrospective and current analysis work could help refine the current recommendations.

Study Type

OBSERVATIONAL

Enrollment

138

Conditions

Phenylketonurias

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with classic or atypical phenylketonuria detected in the neonatal period since 1971 in the department of Nord (59) and Pas de Calais (62). * Patients treated * Able to receive information * Patient beneficiary or affiliated to a social security Exclusion Criteria: * Patients not screened (born outside French territory) or before 1971. * Untreated screened patients * Patients screened for persistent benign hyperphenylalaninaemia not treated with a diet (Phenylalanine level \<10 mg / dl or 600 µmol / l without diet to be confirmed) * Associated confirmed neurological pathology other than a complication of phenylketonuria. * Refusal to participate in the assessment of Intellectual Quotient in adulthood * Patient screened, lost to follow-up, found, having moved to another region and not wishing to return to the CHU for follow-up. * Inability to receive information and or express opposition * Opposition to participation in the study

Outcomes

Primary Outcomes

Adult intelligence quotient (IQ) score

Adult intelligence quotient (IQ) score assessed at the last setback in the two groups defined by the duration of the hypoprotidic diet during childhood

Time frame: Baseline

Secondary Outcomes

The IQ score in adulthood assessed defined by the target Phenylalanine level in one subgroup treated during 8 years.

The IQ score in adulthood assessed at the last time of decline according to the two subgroups treated during 8 years, defined by the target Phenylalanine level ((2-5 mg/dl versus 8-12 mg/dl)

Time frame: Baseline, at the last time of decline (= 8 years of low-protein diet)

The IQ score in adulthood assessed according to the length of expanding the Diet (Phe intake) during childhood for children treated during 10 years (target Phe level 2-5 mg/dl)

The IQ score in adulthood assessed according to length (and degree) of expanding the Diet (increasing Phe intake, during 6 months whatever the Phe levels or longer according the Phe levels) during childhood for children treated during 10 years (xith target Phe level 2-5 mg/dl)

Time frame: Baseline,at the last time of decline (= 10 years of low-protein diet)

The IQ score in adulthood assessed defined by the metabolic biological parameters in childhood

The IQ score in adulthood assessed at the last time of decline according to the metabolic parameters during childhood

Time frame: Baseline

The IQ score in adulthood assessed according to the first phenylalanine level in the target (< 5 mg/dl)

The IQ score in adulthood assessed according to the first phenylalanine level in the target (\< 5 mg/dl) in the neonatal period

Time frame: baseline